YUBIOLOGICS "UKOVEC-19 Phase 3 Clinical Trial Plan Approved in the Philippines"

[Asia Economy Reporter Myunghwan Lee] UbioLogics announced on the 6th that the Phase 3 clinical trial plan (IND) for its COVID-19 preventive synthetic antigen vaccine, 'Ucovac-19,' has been approved.

UbioLogics stated, "Ucovac-19 is a SARS-CoV-2 recombinant protein vaccine that incorporates a liposome-formulated adjuvant, which is expected to provide sufficient COVID-19 preventive effects with a small amount of antigen." They added, "Its advantage of being storable under refrigeration is expected to contribute to overcoming the global COVID-19 pandemic."

The probability of a clinical trial drug receiving final approval as a pharmaceutical product is statistically known to be about 10%. There is a possibility that the results from clinical trials and product approval processes may not meet expectations, which could lead to changes or abandonment of commercialization plans, so caution is advised.